Drug Trial Radar · NCT05112159
Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Sep 27, 2021
Primary completion
Jul 25, 2022
Study completion Jul 25, 2022
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
IPG1094 300 mg SADDrug
a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,300 mg, QD, 3 tablets
IPG1094 600 mg SADDrug
A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days, 600 mg, QD, 6tablets
IPG1094 900 mg SADDrug
A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,900 mg, QD, 9tablets
IPG1094 1200 mg SADDrug
A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,1200 mg, QD, 12 tablets
IPG1094 600 mg MAD QDDrug
Dosing begins on Day 1 and continues for 10 days with daily doses of 600 mg QD.
IPG1094 200 mg MAD BIDDrug
Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo
IPG1094 300 mg MAD BIDDrug
Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo
IPG1094 300 mg Fed-FastedDrug
For Cohort FE-2, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fed condition, and Day 5 (anticipated) of Period 2 under fasted condition.
IPG1094 300 mg Fasted-FedDrug
For Cohort FE-1, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fasted condition, and Day 5 (anticipated) of Period 2 under the fed condition.
IPG1094 100 mg SADDrug
a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,100 mg, QD, 1 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.